In recent days, the attention of investors and analysts has been drawn to a significant deal in the biotechnology sector. The German conglomerate Merck KGaA $MRK.DE has announced plans to acquire SpringWorks Therapeutics Inc. $SWTX, marking a strategic move to strengthen its healthcare division. This development underscores the growing interest in the treatment segments for cancer and rare diseases.
